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Aims Patients with the Brugada type 1 ECG (Br type 1) without previous aborted sudden death (aSD) who do not have
a prophylactic ICD constitute a very large population whose outcome is little known. The objective of this study
was to evaluate the risk of SD or aborted SD (aSD) in these patients.
...................................................................................................................................................................................................
Methods
and results
We conducted a meta-analysis and cumulative analysis of seven large prospective studies involving 1568 patients
who had not received a prophylactic ICD in primary prevention. Patients proved to be heterogeneous. Many were
theoretically at low risk, in that they had a drug-induced Br type 1 (48%) and/or were asymptomatic (87%),
Others, in contrast, had one or more risk factors. During a mean/median follow-up ranging from 30 to 48 months,
23 patients suffered SD and 1 had aSD. The annual incidence of SD/aSD was 0.5% in the total population, 0.9% in
patients with spontaneous Br type 1 and 0.08% in those with drug-induced Br type 1 (P= 0.0001). The paper by
Brugada et al. reported an incidence of SD more than six times higher than the other studies, probably as a result
of selection bias. On excluding this paper, the annual incidence of SD/aSD in the remaining 1198 patients fell to
0.22% in the total population and to 0.38 and 0.06% in spontaneous and drug-induced Br type 1, respectively. Of
the 24 patients with SD/aSD, 96% were males, the mean age was 39 ± 15 years, 92% had spontaneous Br type 1,
61% had familial SD (f-SD), and only 18.2% had a previous syncope; 43% had a positive electrophysiological study.
Multiple meta-analysis of individual trials showed that spontaneous Br type 1, f-SD, and previous syncope increased
the risk of SD/aSD (RR 2.83, 2.49, and 3.03, respectively). However, each of these three risk factors had a very
low positive predictive value (PPV) (1.9–3.3%), while negative predictive values (NPV) were high (98.5–99.7%). The
incidence of SD/aSD was only slightly higher in patients with syncope than in asymptomatic patients (2% vs. 1.5%,
P= 0.6124). Patients with SD/aSD when compared with the others had a mean of 1.74 vs. 0.95 risk factors
(P= 0.026).
...................................................................................................................................................................................................
Conclusion (i) In patients with Br type 1 ECG without an ICD in primary prevention, the risk of SD/aSD is low, particularly in
those with drug-induced Br type 1; (ii) spontaneous Br type 1, f-SD, and syncope increase the risk. However, each
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of these risk factors individually has limited clinical usefulness, owing to their very low PPV; (iii) patients at highest
risk are those with more than one risk factor.
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Introduction
Patients with the Brugada type 1 electrocardiogram (Br type 1 ECG)
without previous aborted sudden death (aSD) who do not undergo
prophylactic implantable cardioverter defibrillator (ICD) implant-
ation constitute a large population.1 According to some authors,2
they account for at least two-third of patients with Br type 1 ECG.
The outcome of these patients, and particularly the characteristics of
those who suffer sudden death (SD) or aSD during follow-up, are lit-
tle known. Indeed, all prospective studies evaluating the outcome of
patients with Br type 1 ECG have considered a combined end-point
composed of fast ventricular arrhythmias (FVA) recorded by ICD
and sudden death (SD) in subjects without ICD.1,3–23 No previous
prospective studies have reported data on patients with SD/aSD
alone, simply because each single study registered only a few cases of
SD/aSD during follow-up in patients without ICD.
In a previous study,1 we made a cumulative analysis of five pub-
lished studies involving patients with Br type 1 without previous car-
diac arrest, in which we separated patients who had ICD from those
without ICD. In patients with ICD, we analysed the prevalence of risk
factors and their sensitivity, specificity, positive predictive values
(PPV), and negative predictive values (NPV). In patients without ICD,
however, this analysis was not possible, because in the original papers
the characteristics of patients without ICD who suffered SD during
follow-up were not available in most cases.
In the present study, we made a cumulative analysis of seven large
published prospective studies after obtaining from the authors them-
selves their original data on patients with Br type 1 ECG who did not
receive a prophylactic ICD for primary prevention. The purpose of
our study was to evaluate the incidence of SD/aSD and risk factors in
this patient population.
Methods
We considered large prospective studies (>49 patients) published be-
tween 2003 and 2013 which involved patients with Br type 1 ECG with-
out previous cardiac arrest.
Studies were selected when, in the total population (patients with and
without ICD), it was possible to separately analyse the characteristics of
those without ICD and to obtain data on their follow-up. If original papers
did not satisfy the inclusion criteria, we asked the authors to send us their
aggregate original data. Authors who did so were included as co-authors.
Studies were excluded if patients with and without ICD were cumula-
tively analysed and/or the authors did not supply original data.
To avoid the double-counting of patients, studies which were subse-
quently included in larger (single- or multi-centre) registries were
excluded.13–18 For example, the study by Giustetto et al.18 was excluded
because a number of patients were included in the study by Probst et al.9
In the selected studies,6–12 all available potential risk factors were ana-
lysed: spontaneous Br type 1 ECG, familial SD (f-SD), syncope, positive
electrophysiological study (þEPS), SCN5A defects and, in more recent
papers, fragmented QRS (f-QRS), and early repolarization (ER) pattern.
In all these studies Br type 1 ECG was defined as a J-point elevation of
>_2 mV with a slowly descending segment followed by flat or negative
T wave (coved type) in at least two right precordial leads.
In multicentre studies of Kamakura et al.,8 Probst et al.,9 Delise et al.,10
and Priori et al.11 all ECG’s were sent to a coordinating Center to validate
the diagnosis.
In these studies, f-SD was generically defined as a family history of un-
explained SD. Only in one paper10 was an age-limit of 40 years adopted.
In various studies, EPS was carried out according to non-homogeneous
protocols; i.e. some studies adopted aggressive protocols (such as triple
extra stimuli and/or premature ventricular beats reaching the ventricular
refractory period),6–8,10–12 while others used less aggressive stimulation
protocols.9
Moreover, not all studies evaluated and/or reported all the above-
mentioned risk factors (e.g. þEPS, ER etc.). Therefore, the total number
of patients varies when single risk factors are considered.
Statistical analysis
We conducted an aggregate meta-analysis of summary statistics from the
individual trials. For each study, data regarding SD mortality and all risk
factors, defined as spontaneous type 1 ECG, f-SD, and syncope, were
used to generate risk ratios (RRs) and 95% confidence intervals (CIs).
Electrophysiological study was excluded from the meta-analysis because
stimulation protocols were non-homogeneous. Since each response
What’s new?
• Patients with the Brugada type 1 electrocardiogram (Br type 1
ECG) who do not have a prophylactic implantable cardi-
overter defibrillator (ICD) in primary or secondary prevention
constitute a very large population whose outcome is poorly
known
• Brugada type 1 patients without an ICD constitute a heteroge-
neous population: most of them theoretically are at low risk, a
few refuse ICD implantation even when it is suggested by
physicians.
• The risk of sudden death (SD) in these patients is low: 0.22%
per year, in the total population, 0.38 and 0.06% per year in
those with spontaneous and drug-induced Br type 1
respectively
• Patients at risk of SD have more than one risk factor (spontan-
eous Br type 1, familial SD, syncope): 1.74 vs. 0.95 (P= 0.026).
• This is the first study in a large population of Br type 1 patients
without ICD which tested risk factors against SD alone, and
not against possibly misleading combined end-points.
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measure was used in a number of different studies, we calculated effect
sizes for each response measure and performed a separate analysis on
each measure. Study-specific estimates were combined by using inverse
variance-weighted averages of logarithmic RRs in random-effect models.
The study by Priori et al. was excluded from all the meta-analyses owing
to lack of information. The study by Mok et al. was excluded from the
meta-analysis regarding f-SD and syncope owing to lack of information.
Between-study heterogeneity was analysed by means v2 P<_ 0.10
deemed statistically significant and I2 for the measure of variation in RR at-
tributable to heterogeneity. To deal with the problem of zero cells in the
2 2 table, we used the standard correction by adding 0.5 to all cells
with 0 before analysis. Sensitivity analyses were also performed to assess
the contribution of each study to the pooled estimate by excluding indi-
vidual trials according to zero cells, where possible. All analyses were per-
formed by means of the statistical software StataSE 12.0 (StataCorp,
College Station, TX, USA).
Cumulative analysis of homogeneous studies was made by calculating
the sensitivity, specificity, PPV, and NPV of risk factors, expressed as both
percentages and proportions.
When considering each risk factor (e.g. spontaneous type 1 ECG), we
classified the presence/absence of this risk factor in patients with SD/aSD
as true positive (TP) and false negative (FN), respectively. Conversely, in
patients without SD/aSD, the presence/absence of this risk factor was
classified as false positive (FP) and true negative (TN), respectively.
Sensitivity was calculated as TP/TPþ FN, Specificity as TN/TNþ FP,
PPV as TP/TPþ FP, and NPV as TN/TNþ FN.
In all statistical tests, a value of P< 0.05 was considered statistically sig-
nificant (when not specified, the P-value should be considered two-tailed).
Results
The seven selected studies6–12 collected a total of 2959 patients. Of
these, 199 patients were excluded because they had had a previous
aSD; 1081 were excluded because they had received an ICD in pri-
mary prevention; 111 belonging to the study by Delise et al.10 were
excluded because were included in another study9 (Table 1). The re-
maining 1568 patients, who had not had a previous cardiac arrest and
had not received an ICD in primary prevention, were enrolled. The
characteristics of these patients are listed in Table 2. Males numbered
1189 (76%) and the mean age was 44 ± 14 years.
This population mainly comprised patients theoretically at low
risk. Indeed, 48% had a drug-induced type 1, 69% had no family his-
tory of SD, 87% were asymptomatic and 83% had a negative EPS.
Nevertheless, a significant number had risk factors: 724 (52%) had a
spontaneous Br type-1 ECG, 420 (31%) f-SD, 183 (13%) previous
syncope, and 155 (17%)þEPS. Regarding other potential risks fac-
tors, two patients (0.7%) had fQRS, 49 (11%) ER and 100 (31%)
SCN5A defects. The characteristics of patients who suddenly died
(n= 23) or had an aSD (n= 1) are listed in Table 3.
The incidence of sudden death was 1.5% (24/1568) over a follow-
up ranging from 30 to 48 months. The annual incidence of SD/aSD
was 0.53% in the general population, 0.9% in patients with spontan-
eous Br type 1 ECG and 0.08% in those with drug-induced Br type 1
ECG (P= 0.0001).
Performing a subanalysis (sensitivity analysis) without the paper of
Brugada6 it emerged that two-thirds of the patients who suffered SD/
aSD were reported in his paper; the event rate reported by these
authors (16/370) was over six times higher than in the remaining
studies (8/1198) (4.3% vs. 0.66%, P< 0.001).
As a consequence, in the absence of the paper by Brugada et al.,6
the annual incidence of SD/aSD among the remaining 1198 patients
fell to 0.22% in the total population, and to 0.38 and 0.06% in those
with spontaneous and drug-induced Br type 1 ECG, respectively.
Sudden death generally occurred during the night (90%), at least in
cases in which this datum was available.
On the basis of multiple meta-analysis (including all studies), spon-
taneous Br type 1 ECG, f-SD, and syncope significantly increased the
risk of SD/aSD. When data from trials were pooled by means of a
random-effects model, spontaneous Br type 1 ECG was associated
with a RR = 2.83 increase (95% CI 0.92–8.71, P= 0.07), f-SD with a
RR = 2.49 (95% CI 1.07–5.80; P= 0.035), and syncope with a
RR = 3.03 (95% CI 1.20–7.67; P= 0.019), as shown in Figure1A–C. On
excluding trials with zero cells, spontaneous Br type 1 ECG reached
statistical significance (RR = 5.1 increase, 95% CI 1.00–25.95,
P= 0.05).
There was no trial heterogeneity except for the higher incidence
on SD/aSD in the paper of Brugada.6
On considering the common risk factors (spontaneous Br type 1
ECG, f-SD, syncope) individually, SD/aSD occurred in 2.9% of
....................................................................................................................................................................................................................
Table 1 Seven selected large studies published between 2003 and 2013. Patients were excluded if they had previous
aborted sudden death (aSD) or an ICD for primary prevention or were included in at least one of the other studies
Studies Total number of
patients with
type 1 ECG
Pts excluded owing to
previous aSD
Pts excluded owing
to ICD in primary
prevention
Pts excluded because
included in other studies
Pts enrolled without
previous aSD and
without ICD
Brugada6 547 0 177 0 370
Mok7 50 8 6 0 36
Kamakura8 245 45 70 0 130
Probst9 1029 62 388 0 579
Delise10* 320 0 110 111 99
Priori 11 308 0 137 0 171
Takagi 12 460 84 193 0 183
Total 2959 199 1081 111 1568
Clinical outcome of patients with the Brugada type 1 ECG f79
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patients with a spontaneous Br type 1 ECG vs. 0.3% of those with a
drug-induced Br type 1 ECG (P= 0.0001), in 3.3% of those with f-SD
vs. 0.8% of those without f-SD (P= 0.006), and in 2% vs. 1.5% of those
with/without syncope (P= 0.6124) (Figure 2). The sensitivity of the
risk factors ranged between 18.2% (syncope) and 91.3% (spontan-
eous type 1 ECG). Specificity ranged from 48.8% (spontaneous
Br type-1 ECG) to 86.6% (syncope). Positive predictive value ranged
between 1.9% (þEPS) and 3.3% (fSD). Negative predictive value
ranged from 98.5% (syncope) to 99.7% (spontaneous type-1 ECG)
(Table 4).
In other words, with the exception of spontaneous Br type 1 ECG,
sensitivity was quite low, particularly that of previous syncope
(18.2%). In addition, each risk factor displayed low specificity and very
low PPV. In contrast, all risk factors had high NPV.
Focusing on patients who suffered SD/aSD (Table 5, Figure 3), it
can be noted that the vast majority of patients with SD/aSD were
males (96%) and had a spontaneous Br type 1 ECG (92%). Most
(61%) had f-SD, while only a few (18.2%) had had syncope before
SD/aSD.þEPS was present in a minority of cases (43%).
Of note, patients who suffered SD/aSD, when compared with
those who had not SD/aSD, had a mean number of risk factors
(Spont. type1 ECG, f-SD, syncope) of 1.74 vs. 0.95 (P= 0.026).
Including among risk factors alsoþEPS, the mean number of risk fac-
tors raised respectively to 2.2 vs. 1.1 (P= 0.011).
Discussion
Patients with the Brugada type 1 ECG without previous aSD and
who do not have an ICD for primary prevention constitute a very
large population, accounting for at least two-third of patients with
the Br type 1 ECG.1 The outcome of these patients is poorly known.
Patients without an ICD for primary prevention constitute a hetero-
geneous population. Indeed, some of these patients do not receive an
ICD because, on the basis of currently considered risk factors, they are
deemed to be at low risk. Others refuse ICD implantation even when
it is suggested by physicians.
....................................................................................................................................................................................................................
Table 2 Characteristics of patients in selected prospective studies without previous aSD or with ICD in primary
prevention
Studies n. pts (males) F.U (months) Age Sp. Type 1 ECG F-SD Syn. 1EPS/EPS fQRS ER SCN5A
Brugada 6 370 (277) 37 ± 30 40 ± 14 231/370 200/370 22/370 25/231 NA NA NA
Mok 7 36 (33) 30 ± 13 55 ± 14 31/36 NA NA NA NA NA NA
Kamakura 8 130 (124) 48 ± 15 52 ± 12 92/130 9/130 14/130 39/64 NA NA NA
Probst 9 579 (382) 32 (14–54) 45 (37–57) 212/579 151/579 102/579 25/295 2/282# 28/282# 100/322#
Delise 10a 99 (77) 40 (20–67) 43 (33–54) 49/99 29/99 19/99 4/58 NA NA NA
Priori 11 171 (137) 36 ± 8) 47 ± 12 NA NA NA 28/171 NA NA NA
Takagi 12 183 (169) 44 ± 30 54 ± 14 109/183 31/183 26/183 34/85 NA 21/183 NA
Total 1568 (1199, 76%) 44 ± 14 724/1397 420/1361 183/1361 155/904 2/282 49/465 100/322
52% 31% 13% 17% 0.7% 10.5% 31%
Sp. Type 1 ECG, spontaneous type 1 ECG; F-SD, family history of juvenile SD; syn., n. pts with syncope; þEPS/EPS, positive EPS (FV induction)/total number of EPS performed;
fQRS, fragmented QRS; ER, early repolarization; SCN5A, positive/performed; NA, not available.
aData excluding cases from Giustetto et al.; #original unpublished data provided by authors.
....................................................................................................................................................................................................................
Table 3 Characteristics of patients without previous cardiac arrest who did not have an ICD and suffered SD or aSD
during follow-up
Studies n. pts (males) n. SD/aSD (M) Noct. SD Age Sp. type 1 ECG F-SD Syn. 1EPS/EPS FQRS ER SCN5A
Brugada et al.6 370 (277) 16 (15) NA 41 ± 15 15/16 11/16 3/16 2/2 NA NA NA
Mok et al.7 36 (33) 1 (1) NA NA 1/1 NA 1/1 1/1 NA NA NA
Kamakura et al.8 130 (124) 1 (1) 1 45 1/1 1/1 0/1 0/1 0/1 0/1 1/1
Probst et al.9 579 (382) 2 (2) 1 24,49 1/2 1/2 0/2 0/1 0/1 0/1 NO
Delise et al.10a 99 (77) 1 (1) NA 39 1/1 0/1 0/1 NA NA NA NA
Priori et al.11 171 (137) 1 aSD NA 23 1/1 0/1 0/1 0/1 NA NA NA
Takagi et al.12 183 (169) 2 (2) 2 45, 52 2/2 1=2 1=2 0/1 NA 1/2 NA
Total 1568 (1199) 24 (23) 4/5 39 ± 15 22/24 14/23 5/24 3/7 0/2 1/4 1/1
% M 96% 90% 92% 61% 21% 43% 0% 25% 100%
n. pts, total number of pts who did not have an ICD; M, males; n.SD/aSD, number of pts who had SD or aSD; Noct. SD, nocturnal SD; Sp.Type 1 ECG, spontaneous type 1
ECG; F-SD, family history of juvenile SD; syn., n. pts with syncope at baseline; þEPS/EPS, positive EPS (FV induction)/total number of EPS performed; fQRS, fragmented QRS;
ER, early repolarization; SCN5A, positive/performed; NA, not available.
aData from Giustetto et al. (included in Probst) excluded.
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Figure 1 Meta-analysis of studies regarding spontaneous Br type 1 ECG (A), family history of SD (B), and syncope (C). (A) Sudden death among pa-
tients with family history of sudden death. (B) Sudden death among patients with Spontaneous Type 1 ECG. (C) Sudden death among patients with
history of syncope. Size of the data marker corresponds to the relative weight assigned in the pooled analysis using random-effects models. RR, risk
ratio; CI, confidence interval.
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In the present study, the first group includes the majority of pa-
tients. Indeed 87% were asymptomatic and only 17% had aþEPS. In
addition, 48% had a drug-induced type 1 and 69% had no family his-
tory of SD. Nevertheless, the population analysed included also a sig-
nificant number of patients with risk factors such as spontaneous Br
type 1 ECG, f-SD, syncope, andþEPS.
This population of patients without ICD offers a unique opportun-
ity to test risk factor against SD/aSD alone, offering data which are
not available in the literature. Indeed, all published prospective stud-
ies1–18 have used a combined end-point composed of FVA recorded
by ICD and SD/aSD in patients without ICD.
In reality, however, ICD-recorded FVA are only a surrogate of SD, as
they may be self-terminating and do not lead necessarily to death.19,20
All the above-mentioned prospective studies have identified a
spontaneous type 1 ECG pattern and syncope as risk factors. In con-
trast, they have demonstrated a low risk in asymptomatic patients
particularly with a drug-induced Br type 1.2–18 Other risk factors
have also been evaluated. Familial SD (f-SD) has proved to have a
controversial prognostic value.2–18,21 The usefulness of EPS has also
been considered controversial for a long time, owing to the different
protocols employed in various studies.2–18 More recently, after per-
forming a meta-analysis of large studies, Sroubeck et al.22 stated that
EPS did have a prognostic value, particularly when non-aggressive
stimulation protocols were employed.
Finally, some new intriguing risk factors have recently been pro-
posed: fragmented QRS, early repolarization, S wave in lead I,
increased ST after effort, ST segment elevation on the peripheral
leads, conduction disturbances.11,12,15,17,23–28
However, again, none of these studies has been able to test risk
factors against SD/aSD alone.
In the present study, we collected only patients without previous
cardiac arrest who had not received an ICD. The results of our cu-
mulative study showed that this population of patients had a low risk
of SD/aSD that is annual incidence of about 0.5%. Our results also
confirm that the risk is significantly different according to whether the
type 1 ECG is spontaneous or drug-induced. Indeed, in the former
case, the annual incidence of SD/aSD proved to be 0.9% per year,
while it was 0.08% in the latter.
However, in the paper by Brugada et al.6 included in this study, the
incidence of SD/aSD was over six times higher than in the other stud-
ies. This particularly high incidence of SD probably reflects a selection
bias, as Brugada’s centre, before 2003, collected complex cases from
all over the world.
Our opinion is confirmed by a recent paper of the Group of
Brugada29 itself which has demonstrated that the incidence of events
in their patients fell down to about one fourth after 2002 in respect
to the population diagnosed before 2002.
On excluding the paper by Brugada from the cumulative valuation,
the annual rate of SD/aSD fell to 0.22% in the total population and to
0.38 and 0.06% in patients with spontaneous and drug-induced Br
type 1, respectively. The latter data probably represent the real actual
incidence of SD/aSD in patients without ICD in primary prevention.
As a consequence, the conservative approach adopted in this
population seems to have been appropriate. For example, in hyper-
trophic cardiomyopathy, a prophylactic ICD is not recommended in
patients with a theoretical risk of SD <5% in 5 years, that is <0.8% %
per year.30
.................................................................................................
Table 4 Sensitivity, specificity, positive predictive
value (PPV), and negative predictive value (NPV) of
main risk factors
Parameter Spont. type 1 ECG Familial SD Syncope 1EPS
Sensitivity 91.3% 63.6% 18.2% 42.9%
Specificity 48.8% 69.7% 86.6% 83.1%
PPV 2.9% 3.3% 2.2% 1.9%
NPV 99.7% 99.1% 98.5% 99.5%
Figure 2 Incidence of SD/aSD according to a spontaneous (sp)
or drug-induced (DI) Br type 1 ECG, familial SD (f-SD), no familial
SD (No f-SD), previous syncope (Syn), and no previous syncope
(Asy).
....................... ...................
.................................................................................................
Table 5 Prospective studies analysing non-ICD pa-
tients without (No SD) or with (SD) sudden death dur-
ing follow-up
No SD SD
n % n. % *P
Cases 1544 100% 24 100%
Males 1166/1544 75% 23/24 96% 0.0179
Age 45 ± 14 39 ± 15 0.27
Nocturnal SD – – 4/5 80% –
Spontaneous type-1 703/1374 51% 22/24 92% 0.0001
Familial SD 409/1339 31% 14/23 62% 0.0015
Previous syncope 179/1339 13% 5/24 21% 0.2502
þEPS/EPS 153/898 17% 3/7 43% 0.0694
f-QRS 2/281 0.7% 0/2 0% 0.6981
ER 49/462 11% 1=4 25% 0.3752
SCN5A 105/358 29% 1/1 100% 0.1189
Mean of four classic RF 1 2.2
Four classic risk factors were: spontaneous type 1 ECG, familial SD, previous syn-
cope, and þEPS.
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In the few patients who died in our cumulative study, multiple ag-
gregate meta-analysis showed that spontaneous Br type 1 ECG, f-SD
and syncope significantly increased the risk of SD/aSD. No meta-
analysis on EPS was performed, owing to the heterogeneous stimula-
tion protocols employed in different studies.6–12
Unfortunately, the clinical usefulness of all the above-mentioned
risk factors appeared to be limited, except when they were absent. In
fact, all classic risk factors had very high NPVs, ranging between
98.4% (syncope) and 99.7% (spontaneous type 1 ECG). In contrast,
when present, all risk factors displayed low specificity and, above all, a
very low PPV (ranging from 1.9 to 3.3%). In particular, the incidence
of SD/aSD was only slightly higher in patients with syncope than in
those who were asymptomatic (2% vs. 1.5%, P= 0.6124) (Figure 2). In
addition the sensitivity of syncope was only 18.2%.
These data regarding prognostic value of syncope are rather sur-
prising. Indeed, most prospective studies2–18 have suggested that syn-
cope is a useful marker of risk.
The similar incidence of SD/aSD in patients with and without syn-
cope probably reflects a high prevalence of vaso-vagal syncope in this
population without ICD.31 And, conversely, patients with syncope
clinically considered of cardiac origin did not took part to this popula-
tion because they had ICD implantation.
As to the low sensitivity of syncope it is not easy to explain al-
though our finding is in agreement with that of Raju et al.,32 who re-
ported that, of 45 subjects with familial Brugada Syndrome who
suddenly died, only 9 (20%) had had syncopal episodes before the
fatal event.
In our study, the high sensitivity of f-SD conflicts with the results of
some studies.2–18,21 However, it is in agreement with a previous study
by our group,10 which showed that f-SD increases the risk when
associated to other risk factors. It is also possible that this discrepancy
with other authors may depend from the different end points of our
and other studies (again, SD/aSD alone and ICD interventionsþ SD/
aSD respectively).
As stated above, the usefulness of EPS could not be fully evaluated
owing to the heterogeneous stimulation protocols used by the vari-
ous authors.
Regarding other risk factors, such as fragmented QRS, early repo-
larization, increased ST after effort, ST segment elevation on the per-
ipheral leads and conduction disturbances, S in I lead which have
been analysed in many studies,11,12,15,17,23–28 no conclusion could be
drawn in our study, owing to the paucity of data available.
Finally, with regard to patients who suffered SD/aSD, it emerged
that SD/aSD generally occurs during night, in males with a spontan-
eous Br type 1 ECG, and at a mean age of around 40 years. These pa-
tients frequently had familial SD, and only rarely had syncopal
episodes before the life-threatening event (Figure 3).
A very important feature of these patients is that they had more
than one risk factor among spontaneous type 1 ECG, f-SD and syn-
cope (mean 1.75 vs. 0.95) (Figure 4). This latter observation confirms
what was suggested by us in 2011 (10) and by Okamura et al. in
2015.33
The recent paper by Sroubeck et al.22 also emphasizes the use-
fulness of multifactorial risk evaluation including EPS. Indeed, in his
study, a þEPS (with up to two extrastimuli) increased the weight
of risk factors such as spontaneous type 1 ECG and previous
syncope.
In conclusion, in patients with the Brugada type 1 ECG without
prior cardiac arrest who do not undergo ICD implantation, the prog-
nosis is fairly good. The few patients who suffer SD/aSD are not easy
to identify because they are generally asymptomatic.
The patients at highest risk have more than one risk factor: spon-
taneous Br type 1, familial SD and/or syncope. Patients with multiple
risk factors should therefore be convinced to undergo ICD implant-
ation, whether they have symptoms or not. By contrast, in patients
without risk factors, or with only single risk factors, including spon-
taneous Br type 1, a conservative approach seems reasonable.
Limitations of the study
As a limit of any meta-analysis there was no allocation of ECG’s by
central reading
Figure 3 Prevalence of risk factors in patients who suffered SD23
or aborted SD1 during follow-up.
Figure 4 Number of risk factors in patients with and without SD/
aSD during follow-up. In the left columns three risk factors (n. RF/3)
were considered (spontaneous type 1 ECG, f-SD, and syncope). In
the right columns four risk factors (n. RF/4) were considered
(including, in addition to spontaneous type 1 ECG, f-SD, and syn-
cope, also þEPS). The differences between with and without SD/
aSD during follow-up were statistically significant (P=0.026 and
0.011 respectively).
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In this study, we performed three aggregate meta-analyses to
evaluate the heterogeneity of studies and the relative risks of the
main risk factors. While meta-analysis of individual patient data (IPD)
would be preferable, IPD were not available in some studies.
However, since aggregate data were obtained from the authors
themselves (in one case from the published paper), we did not ex-
pect significant differences between aggregate meta-analysis and an
individual participant data meta-analysis. For these reasons, we
decided to use standard aggregate-data meta-analysis techniques in
the manuscript.
Patients without an ICD analysed in this study are not representa-
tive of the general population of patients with the Br type 1 ECG, in
that those at highest risk (with previous cardiac arrest and/or signifi-
cant risk factors) generally undergo ICD implantation for secondary
or primary prevention. So the conclusions of this study cannot be ex-
tended to all patients with Brugada Syndrome.
The low incidence of sudden death was probably influenced by the
relatively short follow-up (a mean/median of 30–48 months).
Paradoxically, as in no patient who died autopsy was available, the
risk of SD might have been overestimated. However, other causes of
SD in this relatively young population appear unlikely.
As the present study was not a true prospective study, but a cumu-
lative analysis of previously published studies, many interesting data
were not available. For example, the number of subjects who were
probands and how many family members were affected.
The relatively short follow-up period available for the meta-
analysis did not allow us to predict the risk over a longer period. It is
therefore impossible to say whether this risk is centred around the
age of 40 years (the mean age of the population), or may be cumula-
tive over time, as suggested by Sacher et al.20
Finally, the small number of events22 is a limitation when evaluating
the prognostic value of risk factors. However, the small number of
cases of SD exactly reflects the ‘real-world’ situation in a very large
population of over 1500 cases.
Conclusion
This is the first study to test risk factors against sudden death alone,
and not against possibly misleading combined end-points.
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